Dentsply Sirona Inc SEC Filings

DENTSPLY SIRONA Inc. reported a leadership update, appointing Michael Pomeroy as interim Chief Financial Officer effective November 25, 2025. He will serve in this temporary role while the company searches for a permanent Chief Financial Officer.

During this period, President and Chief Executive Officer Daniel T. Scavilla will continue to act as the company’s principal financial officer in addition to his role as principal executive officer. Pomeroy brings extensive finance leadership experience across industrial, healthcare, consumer, and distribution businesses, including prior CFO roles at Icahn Automotive Group, Hollander-Keeco, and RGIS, and a recent interim CFO role at spinal devices company Highridge Medical.

DENTSPLY SIRONA (XRAY) disclosed a Form 4 for an officer, SVP and Chief Supply Chain Office, reporting two stock option grants on 11/07/2025. The filings show awards of 417,200 options at an exercise price of $11.18 and 361,700 options at $12.3, each recorded as an acquisition (Code A) with $0 option price, indicating grants. Both grants are held directly and will cliff-vest on the third anniversary of the grant date (11/07/2028), with expiration on 11/07/2035. The second grant’s exercise price equals 110% of the issuer’s closing price on the grant date.

DENTSPLY SIRONA filed an 8-K/A to disclose separation terms for former CFO Matthew E. Garth. The Separation Agreement provides separation payments totaling $1,200,000, paid in two installments of $600,000 each, plus $32,430 for twelve months of COBRA coverage and twelve months of outplacement services.

Mr. Garth remains eligible to earn a prorated portion (5/36ths) of his May 30, 2025 performance restricted share units based on actual achievement at the end of the performance period. All other unvested equity is forfeited and canceled. Payments and benefits are contingent on his execution and nonrevocation of a release of claims and compliance with post-termination restrictive covenants.

Dentsply Sirona (XRAY) reported Q3 2025 results with net sales of $904 million versus $951 million a year ago and an operating loss of $218 million. The quarter included $262 million of goodwill and intangible asset impairments, leading to a net loss of $427 million, or $2.14 per share.

Sales declined in the United States to $291 million from $374 million, while Europe rose to $382 million from $347 million. Segment mix showed Essential Dental Solutions at $357 million and Orthodontic and Implant Solutions at $205 million; Wellspect Healthcare increased to $83 million from $72 million.

Year to date, net sales were $2.719 billion versus $2.888 billion, with $497 million of impairments and a net loss of $452 million. Cash from operating activities was $134 million year to date, ending cash was $363 million. Long‑term debt was $2,017 million and current debt was $378 million. Goodwill decreased to $1,270 million from $1,597 million, and total equity was $1,478 million.

DENTSPLY SIRONA (XRAY) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 under Item 2.02. The company notes this information is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities or incorporation by reference unless specifically referenced.

DENTSPLY SIRONA (XRAY) announced a leadership change. On October 31, 2025, the company determined that Matthew E. Garth will no longer serve as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun a search for its next CFO. The filing states Mr. Garth’s departure was not due to any disagreement regarding financial statements, internal controls, or operations.

Effective upon Mr. Garth’s departure, Daniel T. Scavilla, the company’s President and CEO and a director, was appointed as interim principal financial officer for SEC reporting. The company noted no new compensatory arrangements for Mr. Scavilla related to these additional responsibilities, and no related‑party relationships were disclosed.

DENTSPLY SIRONA (XRAY) reported an insider transaction by President & CEO and Director Daniel T. Scavilla. On 10/10/2025, he acquired 223.681 restricted stock units (RSUs) at $0, recorded as dividend equivalents on existing RSUs. Following this, his beneficial ownership stands at 17,698.73 shares, held directly.

The filing notes these RSU dividends carry the same vesting schedule as the underlying awards, and each RSU converts to one share of common stock upon vesting.

DENTSPLY SIRONA (XRAY) filed a Form 4 for an executive equity accrual. On 10/10/2025, the SVP, Chief Supply Chain Office reported 972.381 shares of common stock acquired at $0, credited as dividends on restricted stock units that vest with the underlying awards and convert 1:1 into common stock.

The filing also reports 40.5116 phantom stock units under the SERP acquired at $11.98, each economically equivalent to one share and payable in stock upon termination of employment. Following these entries, direct ownership stands at 124,187.521 common shares and 3,072.9326 phantom stock units.

DENTSPLY SIRONA (XRAY) reported an initial statement of beneficial ownership for executive Aldo Mariano Roberto Denti. The filing notes he serves as EVP, Chief Commercial Officer and indicates no securities are beneficially owned.

The Form 3 lists the Date of Event as 10/06/2025 and was filed by a single reporting person. An Exhibit 24 Power of Attorney is included, with the form signed by an attorney-in-fact on the executive’s behalf.